The biopharmaceutical sector is a cornerstone of medical innovation, yet the journey from concept to market is fraught with challenges. For startups and established firms alike, navigating the complex landscape of funding, regulation, and commercialization is a daunting task. In 2026, Europe finds itself at a critical juncture, as a new report by Charles River Associates (CRA) highlights the region’s declining appeal as an investment destination compared to the US and China.
This comprehensive analysis delves into the policy environments that influence key decisions in the biopharmaceutical sector, with a particular focus on the hurdles faced by smaller companies. The findings underscore Europe’s need to bolster its competitive edge to attract and retain biotech investment.
The Global Biotech Race
Europe’s leadership in scientific research is well-established, but the CRA report reveals a stark contrast in the region’s ability to translate this strength into commercial success. While the US and China are rapidly attracting life sciences investment and fostering biotech growth, Europe is lagging behind in several critical areas, from clinical trials to patent filings. The cost and complexity of operating in Europe weigh heavily on both large biopharmaceutical companies and smaller biotech firms.
The EU Biotech Act, introduced in, aims to simplify regulatory pathways and shorten time-to-market. However, the report concludes that these measures alone will not be sufficient to bridge the gap between Europe and its global competitors. To remain competitive, Europe must build on its existing strengths and implement ambitious actions to create a more attractive environment for pharmaceutical investment.
Key Factors Influencing Investment Decisions
The CRA report identifies five key factors that determine investment decisions in the biopharmaceutical sector. These factors include access to venture capital, intellectual property (IP) protection, regulatory incentives, clinical development efficiency, and the ease of setting up production and launching products.
Foundations for Success
The US leads the way in providing venture capital funding, intellectual property protection, and regulatory incentives for early-stage biotech companies. In contrast, Europe’s traditional strengths in scientific research are not translating into commercial outcomes. The US holds a strong lead in new patents, while China has significantly increased its share of biotech patent filings. Europe’s relative weakness in supporting biotech startups is evident in recent trends, with most EU biotech companies choosing to list outside of the region.
Clinical Development
Clinical trial start-up times in the US are shorter than in the EU, although the cost of running a trial can be higher. However, the US’s strong commercial environment provides greater opportunities to attract investment and recoup R&D spending. China, meanwhile, has developed a highly cost-efficient environment for clinical research. Europe’s share of commercially sponsored clinical trials has fallen significantly, raising concerns about the future of its biotech sector.
Setting Up Production
Finding technically skilled staff and securing funding for contract manufacturing organizations (CMOs) are major challenges for smaller biotech companies. The process of bringing a product through clinical development and scaling up manufacturing is long and uncertain, with no guarantee of success. These hurdles can be devastating to companies reliant on venture capital.
Preparing to Launch
Europe’s approach to launching new medicines is particularly cumbersome, requiring central marketing authorization from the European Medicines Agency (EMA) and additional country-specific Health Technology Assessment (HTA) processes. In contrast, the US offers faster marketing authorization and does not require HTA filings. This bureaucratic burden can deter companies from launching their products in Europe.
Maintaining a Presence
Pharmaceutical companies operating in Europe face clawbacks and mandatory rebates, which can significantly impact their profitability. Neither China nor the US imposes such limits on profitability, making Europe a less appealing place to do business. For smaller companies reliant on venture capital, the reduced prospects of a return on investment can be devastating to their fundraising efforts.
The Impact of the Biotech Act
The EU Biotech Act acknowledges several of the challenges outlined in the CRA report. It includes measures designed to narrow the gap between Europe and its global competitors, such as reforms on clinical trials and regulatory timelines, as well as broader commitments to increase public and private funding. However, the report suggests that the Biotech Act’s impact on competitiveness will be limited unless it is accompanied by measures that strengthen the commercial environment.
As the US and China continue to invest heavily in strengthening their biotech ecosystems, Europe must seize this moment to go beyond where its competitors are today. By building on its existing strengths and implementing ambitious actions, Europe can shape the future of the biopharmaceutical sector and secure its position as a global leader in medical innovation.
